Pancreatectomy — Procedure Guide, Recovery & Risks | MyMedicPlus

Pancreatectomy is the surgical removal of part or all of the pancreas, an organ with critical exocrine (digestive enzyme) and endocrine (insulin, glucagon) functions. Three principal operations are performed: the pancreaticoduodenectomy (Whipple procedure), which removes the pancreatic head, duodenum, bile duct, and gallbladder; distal pancreatectomy, which removes the body and tail; and total pancreatectomy, which removes the entire gland. The choice of procedure is determined by tumour location, extent of disease, and involvement of adjacent structures. All forms are among the most technically complex abdominal operations, associated with significant morbidity even at experienced centres. Pancreatectomy is the only potentially curative option for pancreatic malignancies and high-risk cystic lesions. High-volume centres performing more than 20 resections per year achieve substantially lower mortality and complication rates than low-volume hospitals. The pancreatic remnant following distal pancreatectomy is typically closed with a stapling device or hand-sewn technique. Reconstruction after Whipple procedure connects the pancreatic remnant, bile duct, and stomach or duodenum to the jejunum — three separate anastomoses. Operative time ranges from 4–8 hours. Central pancreatectomy (middle segment resection) preserves both the head and tail of the pancreas, reducing the risk of post-operative diabetes while allowing resection of benign neck/body tumours. Total pancreatectomy removes all insulin and glucagon secretion, requiring insulin therapy and enzyme replacement for life.

Pancreatectomy is indicated for pancreatic ductal adenocarcinoma (PDAC) without involvement of the portal vein, superior mesenteric artery, or coeliac axis (resectable disease), pancreatic neuroendocrine tumours (PNETs) of any grade if localised, intraductal papillary mucinous neoplasm (IPMN) with worrisome features or high-risk stigmata, chronic pancreatitis causing intractable pain where medical management has failed, solid pseudopapillary neoplasm, distal cholangiocarcinoma, ampullary carcinoma, and duodenal adenocarcinoma. Borderline-resectable PDAC may be treated with neoadjuvant chemotherapy before surgery to achieve resectability. Resectability requires the absence of distant metastases and no circumferential encasement of major mesenteric vessels, assessed by high-quality cross-sectional CT and/or MRI. Patients require thorough nutritional optimisation, diabetes management, and performance status assessment before major pancreatic resection. Indications also include symptomatic or growing pancreatic neuroendocrine tumours (pNETs), which have variable malignant potential. Insulinomas (usually benign), gastrinomas, and non-functional pNETs over 2 cm are managed surgically. Chronic pancreatitis with intractable pain not responding to endoscopic or medical therapy may be managed with partial or total pancreatectomy with islet autotransplantation (TP-IAT), which aims to prevent or reduce post-operative diabetes by re-infusing the patient's own islet cells into the liver.

The Whipple procedure (pancreaticoduodenectomy) is performed via open midline laparotomy or minimally invasive (laparoscopic or robotic) approach at experienced centres. After exploratory laparoscopy to exclude metastases, the resection removes the pancreatic head, duodenum, first 15 cm of jejunum, gallbladder, and common bile duct. Three anastomoses are then constructed to restore gastrointestinal continuity: a pancreaticojejunostomy (pancreatic remnant to jejunum), a hepaticojejunostomy (bile duct to jejunum), and a gastrojejunostomy or duodenojejunostomy. Distal pancreatectomy removes the body and tail with en bloc splenectomy in most cases; splenic preservation is possible in benign disease. Total pancreatectomy is reserved for diffuse tumours or main duct IPMN involving the entire gland. Intraoperative margin assessment with frozen section ensures R0 (clear margin) resection — the primary oncological goal. Duration is 4–8 hours. High-volume centres with dedicated HPB surgical teams achieve the lowest complication and mortality rates. The Whipple procedure (pancreaticoduodenectomy) involves en-bloc resection of the pancreatic head, duodenum, distal common bile duct, and often the gallbladder and distal stomach. Three anastomoses reconstruct GI continuity: pancreaticojejunostomy (or pancreaticogastrostomy), hepaticojejunostomy, and gastrojejunostomy (Roux-en-Y). Distal pancreatectomy removes the body and tail, usually with splenectomy due to shared blood supply. Spleen-preserving distal pancreatectomy is feasible for benign tumours using Kimura (vessel-preserving) or Warshaw (splenic vessel-sacrificing) techniques.

R0 resection is the primary oncological goal of pancreatectomy. For resectable pancreatic ductal adenocarcinoma, median overall survival with R0 resection and adjuvant chemotherapy (modified FOLFIRINOX) is 54 months — compared with under 12 months without surgery. Five-year survival for resected PDAC is 15–25%, and 20–30% for R0 margins with favourable tumour biology. Pancreatic neuroendocrine tumours have substantially better prognosis: 5-year survival exceeds 60–70% after complete resection of well-differentiated PNETs. Ampullary carcinoma and distal cholangiocarcinoma have 5-year survival of 30–50% after R0 resection. Robotic and laparoscopic distal pancreatectomy achieve equivalent oncological outcomes to open surgery with shorter hospital stay and reduced blood loss at high-volume minimally invasive HPB centres. Pancreatectomy offers the only potentially curative treatment for pancreatic adenocarcinoma. R0 resection (clear margins) is associated with median survival of 20–24 months and 5-year survival of 20–25%. Adjuvant chemotherapy (gemcitabine plus capecitabine or modified FOLFIRINOX) further improves survival after resection. Symptom relief — relief of obstructive jaundice, pain, and weight loss — is achieved even in patients with borderline-resectable or palliative-intent surgery.

The Whipple procedure carries 30-day mortality of 3–5% at high-volume specialist centres (up to 15% at low-volume hospitals) — the strongest argument for referral to experienced HPB units. The most characteristic major complication is postoperative pancreatic fistula (POPF), classified Grade A–C, occurring in 10–20% of Whipple procedures when the pancreatic duct is soft and small. Delayed gastric emptying (requiring nasogastric tube and prolonged hospitalisation) affects 20–30%. Post-pancreatectomy haemorrhage, bile leak, surgical site infection, venous thromboembolism, and anastomotic stricture are additional risks. Distal pancreatectomy carries a lower pancreatic fistula risk than the Whipple (10–15% Grade B/C). All forms of pancreatectomy may cause exocrine insufficiency (malabsorption, steatorrhoea) requiring lifelong pancreatic enzyme replacement therapy. Pancreatic fistula is graded A (biochemical, clinically insignificant), B (requiring interventional drainage), or C (major morbidity, ICU). Post-operative pancreatic fistula (POPF) rates of 10–20% are managed with percutaneous drainage and octreotide. Delayed gastric emptying causes nausea and inability to eat for 5–14 days in 20–30% of patients. Bile leak, wound infection, and sepsis are additional complications. Post-pancreatectomy diabetes (type 3c) occurs in 20–50% of patients depending on resection extent and pre-existing pancreatic exocrine and endocrine function.

Enhanced recovery after surgery (ERAS) protocols allow early oral fluid intake by day 2–3 and diet introduction by day 3–5, with the goal of discharge between days 7–10. Nasogastric tube and drains are removed as clinically indicated. Pancreatic enzyme replacement therapy (PERT — e.g., pancrelipase 25,000–50,000 units with each meal) is initiated for exocrine insufficiency and titrated to stool consistency. Diabetes management begins immediately after total pancreatectomy; brittle pancreatogenic (Type 3c) diabetes requires insulin therapy with a specialist endocrinology team. Patients undergoing adjuvant chemotherapy (modified FOLFIRINOX or gemcitabine plus capecitabine) begin treatment 6–8 weeks post-operatively after wound healing. Serial CA 19-9, CT abdomen, and clinical review are performed every 3 months for 2 years then 6-monthly for surveillance. Full functional recovery takes 3 months.